https://www.viatris.jp/ja-jp 2023-11-20 daily 0.5 https://www.viatris.jp/ja-jp/about-us 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/products 2025-02-12 daily 0.5 https://www.viatris.jp/ja-jp/drug-development 2025-01-24 daily 0.5 https://www.viatris.jp/ja-jp/drug-development 2025-01-24 daily 0.5 https://www.viatris.jp/en/drug-development 2024-07-30 daily 0.5 https://www.viatris.jp/ja-jp/newsroom 2025-06-06 daily 0.5 https://www.viatris.jp/ja-jp/careers 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/investors 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/プライバシー通知 2025-09-30 daily 0.5 https://www.viatris.jp/ja-jp/クッキー通知 2023-02-17 daily 0.5 https://www.viatris.jp/ja-jp/利用規約 2023-05-03 daily 0.5 https://www.viatris.jp/ja-jp/404 2023-03-15 daily 0.5 https://www.viatris.jp/ja-jp/search 2022-07-18 daily 0.5 https://www.viatris.jp/ja-jp/viatris-pharmaceutical 2023-03-07 daily 0.5 https://www.viatris.jp/ja-jp/about-us/our-mission 2025-05-08 daily 0.5 https://www.viatris.jp/ja-jp/about-us/our-leaders 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/about-us/company-profile 2023-04-11 daily 0.5 https://www.viatris.jp/ja-jp/about-us/corporate-social-responsibility 2023-05-19 daily 0.5 https://www.viatris.jp/ja-jp/about-us/business-development 2026-03-18 daily 0.5 https://www.viatris.jp/ja-jp/about-us/public-policy 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/about-us/お問い合わせ 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/about-us/document-library--na 2022-08-04 daily 0.5 https://www.viatris.jp/ja-jp/products/therapeutic-areas 2025-05-21 daily 0.5 https://www.viatris.jp/ja-jp/products/product-details--na 2022-08-04 daily 0.5 https://www.viatris.jp/ja-jp/products/product-information 2025-02-12 daily 0.5 https://www.viatris.jp/ja-jp/products/疾患情報 2025-01-28 daily 0.5 https://www.viatris.jp/ja-jp/drug-development/development-items 2024-07-24 daily 0.5 https://www.viatris.jp/ja-jp/drug-development/clinical-trial-information 2024-07-23 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release 2024-04-01 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release-global 2024-03-27 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/notice 2024-04-01 daily 0.5 https://www.viatris.jp/ja-jp/careers/viatris-japan-career 2024-10-23 daily 0.5 https://www.viatris.jp/ja-jp/careers/diversity-and-inclusion 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/careers/working-at-viatris--na 2022-08-04 daily 0.5 https://www.viatris.jp/ja-jp/investors/events-and-presentations 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/investors/financials-and-filings 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/investors/stock-information 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/investors/shareholder-toolkit 2023-04-25 daily 0.5 https://www.viatris.jp/ja-jp/investors/frequently-asked-questions 2023-09-12 daily 0.5 https://www.viatris.jp/ja-jp/about-us/our-mission/our-journey--na 2022-07-18 daily 0.5 https://www.viatris.jp/ja-jp/about-us/our-leaders/sun-a 2022-07-19 daily 0.5 https://www.viatris.jp/ja-jp/about-us/corporate-social-responsibility/partnerships 2022-07-20 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/atorvastatin-approval 2024-10-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/escitalopram-approval 2024-10-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/ibandronate-approval 2024-10-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/atorvastatin-launch 2024-10-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/escitalopram-launch 2024-10-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/ibandronate-launch 2024-10-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/ncds-white-paper 2024-10-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/cystadrops-application 2024-10-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/tacrolimus_additional_indication 2024-10-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/clinical_trial_vr205 2024-12-25 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/co_promotion 2024-12-25 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/obtained-manufacturing-and-marketing-approval 2024-12-25 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/obtained-manufacturing-and-marketing-approval_2 2024-12-25 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/sugammadex-intravenous-solution 2024-12-25 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/sugammadex-intravenous-solution_2 2024-12-25 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/effexor-gad-clinical-topline 2024-12-25 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/submission_effexor_gad 2025-04-21 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/acquisition-of-aculys-pharma 2025-10-16 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/launch-sypdia 2025-12-24 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/clinical-trial-selatogrel 2025-10-27 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/publication-effexor-gad 2026-01-08 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/press-release/approval-effexor-gad 2026-03-23 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/notice/donation-for-noto-peninsula-earthquake 2024-07-05 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/notice/head-office-relocation 2024-06-25 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/notice/information-on-voluntary-inspections 2024-10-08 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/notice/self-inspection 2024-08-14 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/notice/self-inspection-regarding-sales-approval-of-generic-drugs 2024-11-11 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/notice/voluntary-inspection 2024-07-12 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/notice/voluntary-inspection-2024-9-11 2024-09-09 daily 0.5 https://www.viatris.jp/ja-jp/newsroom/notice/medii 2025-11-18 daily 0.5